Vistagen Therapeutics, Inc. 8-K

What Happened Vistagen Therapeutics (filed 8-K on March 11, 2026; Item 8.01) announced a Board‑approved reduction in force of approximately 20% of its workforce. The move is intended to conserve cash while prioritizing continued execution of its PALISADE Program for fasedienol (acute treatment of social anxiety disorder). The company expects topline results from the PALISADE‑4 Phase 3 trial in the first half of 2026 and says it has a cash runway into 2027. The filing was signed by CEO Shawn K. Singh.

Key Details

• Reduction size: approximately 20% of employees (Board‑approved).
• Clinical timeline: topline results from PALISADE‑4 Phase 3 expected in H1 2026.
• Cash outlook: company expects cash runway into 2027.
• Employee terms: affected employees may be eligible for cash severance and temporary healthcare if they sign a separation agreement containing a general release; company expects related costs to be immaterial but may incur additional unforeseen costs.

Why It Matters This filing signals management is actively cutting operating costs to extend runway while focusing resources on the PALISADE Phase 3 program and an imminent topline readout. For investors, the most material items are the 20% headcount reduction (which can lower near‑term burn) and the timing of PALISADE‑4 topline results (H1 2026), which could be a key catalyst for the stock. The company’s stated cash runway into 2027 is important for assessing dilution risk and near‑term financing needs. The 8-K also contains standard forward‑looking statement disclaimers; outcomes and costs may differ from current expectations.